• Something wrong with this record ?

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer

W. Voigt, C. Manegold, L. Pilz, YL. Wu, L. Müllauer, R. Pirker, M. Filipits, J. Niklinski, L. Petruzelka, H. Prosch,

. 2020 ; 32 (1) : 68-77. [pub] -

Language English Country United States

Document type Journal Article, Review

PURPOSE OF REVIEW: The objective of this review is to discuss the strength and limitations of tissue and liquid biopsy and functional imaging to capture spatial and temporal tumor heterogeneity either alone or as part of a diagnostic framework in non-small cell lung cancer (NSCLC). RECENT FINDINGS: NSCLC displays genetic and phenotypic heterogeneity - a detailed knowledge of which is crucial to personalize treatment. Tissue biopsy often lacks spatial and temporal resolution. Thus, NSCLC needs to be characterized by complementary diagnostic methods to resolve heterogeneity. Liquid biopsy offers detection of tumor biomarkers and for example, the classification and monitoring of EGFR mutations in NSCLC. It allows repeated sampling, and therefore, appears promising to address temporal aspects of tumor heterogeneity. Functional imaging methods and emerging image analytic tools, such as radiomics capture temporal and spatial heterogeneity. Further standardization of radiomics is required to allow introduction into clinical routine. SUMMARY: To augment the potential of precision therapy, improved diagnostic characterization of tumors is pivotal. We suggest a comprehensive diagnostic framework combining tissue and liquid biopsy and functional imaging to address the known aspects of spatial and temporal tumor heterogeneity on the example of NSCLC. We envision how this framework might be implemented in clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025299
003      
CZ-PrNML
005      
20201222155141.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/CCO.0000000000000598 $2 doi
035    __
$a (PubMed)31714259
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Voigt, Wieland $u Medical Innovations and Management, Steinbeis University Berlin, Berlin, Germany.
245    10
$a Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer / $c W. Voigt, C. Manegold, L. Pilz, YL. Wu, L. Müllauer, R. Pirker, M. Filipits, J. Niklinski, L. Petruzelka, H. Prosch,
520    9_
$a PURPOSE OF REVIEW: The objective of this review is to discuss the strength and limitations of tissue and liquid biopsy and functional imaging to capture spatial and temporal tumor heterogeneity either alone or as part of a diagnostic framework in non-small cell lung cancer (NSCLC). RECENT FINDINGS: NSCLC displays genetic and phenotypic heterogeneity - a detailed knowledge of which is crucial to personalize treatment. Tissue biopsy often lacks spatial and temporal resolution. Thus, NSCLC needs to be characterized by complementary diagnostic methods to resolve heterogeneity. Liquid biopsy offers detection of tumor biomarkers and for example, the classification and monitoring of EGFR mutations in NSCLC. It allows repeated sampling, and therefore, appears promising to address temporal aspects of tumor heterogeneity. Functional imaging methods and emerging image analytic tools, such as radiomics capture temporal and spatial heterogeneity. Further standardization of radiomics is required to allow introduction into clinical routine. SUMMARY: To augment the potential of precision therapy, improved diagnostic characterization of tumors is pivotal. We suggest a comprehensive diagnostic framework combining tissue and liquid biopsy and functional imaging to address the known aspects of spatial and temporal tumor heterogeneity on the example of NSCLC. We envision how this framework might be implemented in clinical practice.
650    _2
$a biopsie $x metody $7 D001706
650    _2
$a genetická heterogenita $7 D018740
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x diagnóza $x genetika $x patologie $x terapie $7 D008175
650    _2
$a individualizovaná medicína $x metody $7 D057285
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Manegold, Christian $u Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Pilz, Lothar $u Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Wu, Yi-Long $u Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China.
700    1_
$a Müllauer, Leonard $u Department of Pathology, Medical University of Vienna, Austria.
700    1_
$a Pirker, Robert $u Department of Medicine, Medical University of Vienna, Austria.
700    1_
$a Filipits, Martin $u Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria.
700    1_
$a Niklinski, Jacek $u Department of Clinical Molecular Biology, Medical University of Bialystok, Poland.
700    1_
$a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine Charles University Prague and General University Hospital Prague, Czech Republic.
700    1_
$a Prosch, Helmut $u Department of Biomedical Imaging and Image-Guided Therapy Medical University of Vienna, Austria.
773    0_
$w MED00001292 $t Current opinion in oncology $x 1531-703X $g Roč. 32, č. 1 (2020), s. 68-77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31714259 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155137 $b ABA008
999    __
$a ok $b bmc $g 1599444 $s 1115985
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 32 $c 1 $d 68-77 $e - $i 1531-703X $m Current opinion in oncology $n Curr. Opin. Oncol. $x MED00001292
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...